

例 #4, #7 に関しては、試験終了後も観察を継続しており、HIV-RNA 量の変動により、**BID** への変更も検討している。

試験期間に発現した有害事象はいずれも軽微であり、嘔気、胃部不快感などの消化器症状は服薬後数時間で発現し、時間経過とともに消失する例が多かった。これは、**QD** への変更で服用後の血中濃度が **BID** に比べ上昇したことによって発現した症状であると考えられた。また、これらの症状が時間経過と共に消失したことから、血中濃度の上昇による副作用は、時間経過とともに軽減できる症状であったと考えられた。予想された下痢の頻度が海外報告に比べ少なかったことから、今回の試験における **QD** の忍容性を確認することができた。本試験の対象となった患者は、すでに **LPV/r** を **BID** で服用した経験を有していたことが、下痢の頻度の少なかった要因の一つであると推測された。

本試験を実施した結果、**QD** は **BID** と同等のウイルス抑制効果を持ち、**CD4** 細胞数の維持が可能であることが確認され、試験期間中に脂質代謝パラメータの変動、重篤な有害事象が認められなかったことから、24 週間における安全性と有効性を確認することができた。日本では現在 **QD** の適応はないものの、今回の結果が日本における **QD** 投与の有用性確認の第一歩となったものとする。

## 文 献

- 1) Kaletra [patient information] Chicago, Illinois Abbott Laboratories. November, 2007. Available at : <http://www.rxabbott.com/pdf/kaletratabpi.pdf> June, 2008.
- 2) The Department of Health and Human Services : Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, revised on November 3, 2008.
- 3) Johnson MA, Gathe JC Jr, Podzamczar D, Molina JM, Naylor CT, Chiu YL, King MS, Podsadecki TJ, Hanna GJ, Brun SC : A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. *J Acquir Immune Defic Syndr* 43 : 153-160, 2006.
- 4) Eron JJ, Feinberg J, Kessler HA, Horowitz HW, Witt MD, Carpio FF, Wheeler DA, Ruane P, Mildvan D, Yangco BG, Bertz R, Bernstein B, King MS, Sun E : Once-Daily versus twice-daily lopinavir/ritonavir in antiretroviral-naïve HIV-positive patients : A 48-week randomized clinical trial. *The Journal of Infectious Diseases* 189 : 265-272, 2004.
- 5) Stryker R, Brun S, King M, Marsh T, Murphy R, Hicks C, Eron JJ, Thommes J, Glesby M, Thompson M, White C, Benson C, Albrecht M, Kessler H, Real K, Japour A, Perrin L, Sun E : ABT-378/ritonavir in atinretroviral-naive HIV+Patients : Follow-up beyond two years and viral load suppression below 3 copies/mL. 5th International Congress on Drug Therapy in HIV Infection, Glasgow, UK : October 22-26, 2000.
- 6) Murphy RL, da Silva BA, Hicks CB, Eron JJ, Gulick RM, Thompson MA, McMillan F, King MS, Hanna GJ, Brun SC : Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naive HIV-1-infected patients. *HIV Clinical Trials* 9 : 1-10, 2008.
- 7) Acosta EP, Gerber JG and Adult Pharmacology Committee of the AIDS Clinical Trials Group : Position paper on therapeutic drug monitoring of antiretroviral agents. *AIDS Res Hum Retroviruses* 18 : 825-834, 2002.
- 8) Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, Del Giudice P, Montagne N, Schapiro JM, Dellamonica P : Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy : pharmacological data from the Viradapt Study. *AIDS* 14 : 1333-1339, 2000.
- 9) Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, Kurowski M, Lubner A, Merry C, Perno CF : Therapeutic drug monitoring in HIV infection : current status and future directions. *AIDS* 16 : 5-37, 2002.
- 10) Maggiolo F, Airoldi M, Kleinloog HD, Callegaro A, Ravasio V, Arici C, Bombana E, Suter F : Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. *HIV Clinical Trials* 8 : 282-292, 2007.
- 11) Schrader S, Chuck SK, Rahn LW, Parekh PS, Emrich KG : Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules. *AIDS Research and Therapy* 17 : 5-21, 2008

## Results of Switching Lopinavir/Ritonavir from Twice Daily to Once Daily Dosing

Munehiro YOSHINO<sup>1)</sup>, Hiroki YAGURA<sup>1)</sup>, Takeshi KUWAHARA<sup>2)</sup>, Hiroki BANDO<sup>3)</sup>,  
Yoshihiko OGAWA<sup>3)</sup>, Keishiro YAJIMA<sup>3)</sup>, Tomohiro TANIGUCHI<sup>3)</sup>, Naruhito OTANI<sup>3)</sup>,  
Shinjiro TOMINARI<sup>3)</sup>, Dai WATANABE<sup>3)</sup>, Yasuharu NISHIDA<sup>3)</sup>,  
Tomoko UEHIRA<sup>3)</sup> and Takuma SHIRASAKA<sup>3)</sup>

<sup>1)</sup> Department of Pharmacy, National Hospital Organization Osaka National Hospital

<sup>2)</sup> Department of Pharmacy, National Hospital Organization Minami Kyoto National Hospital

<sup>3)</sup> AIDS Medical Center, National Hospital Organization Osaka National Hospital

**Objectives** : We examined the efficacy and safety of switching patients with lopinavir (LPV) trough concentrations of  $6.00\mu\text{g/mL}$  or more on twice daily (bid) lopinavir/ritonavir (LPV/r) dosing to once daily.

**Subjects and Methods** : Eight patients at our hospital treated with LPV/r bid with LPV trough concentrations over  $6.00\mu\text{g/mL}$  were enrolled in this study. Adverse events, trough concentrations, HIV-RNA loads, CD4 cell counts, total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides were examined 4, 8, 12, 16, 20, and 24 weeks after switching to once daily dosing and compared to the levels during bid dosing.

**Results** : The LPV trough concentration of the eight enrolled patients before the switch was  $10.99\pm 2.75\mu\text{g/mL}$  (mean  $\pm$  SD, range 7.46–5.85). Although the mean LPV trough concentration declined to  $2.28\pm 1.72\mu\text{g/mL}$  (range 0.41–5.85) 4 weeks after the switch, the HIV-RNA load remained undetectable for all subjects throughout the 24-week study. No changes in CD4 cell counts, total cholesterol, HDL cholesterol, or triglycerides were observed. Gastrointestinal symptoms, such as constipation and nausea, emerged as new adverse events, but the increase in diarrhea was minimal.

**Conclusions** : Switching patients with relatively high LPV blood concentrations and a stable clinical course to once daily dosing was confirmed to be safe and effective for 24 weeks. We consider the results to be the first step in confirming the efficacy of once daily dosing in Japan.

**Key words** : HAART, lopinavir, ritonavir, pharmacokinetics, once daily

## 研究ノート

## 硫酸アタザナビルの血中濃度が高値の患者を対象とした、 ATV/r から ATV<sub>400</sub> へのスイッチ臨床試験結果

吉野 宗宏<sup>1</sup>, 矢倉 裕輝<sup>1</sup>, 栗原 健<sup>2</sup>, 坂東 裕基<sup>3</sup>, 小川 吉彦<sup>3</sup>, 矢嶋 敬史郎<sup>3</sup>,  
谷口 智宏<sup>3</sup>, 大谷 成人<sup>3</sup>, 富成 伸次郎<sup>3</sup>, 渡邊 大<sup>3</sup>, 上平 朝子<sup>3</sup>, 白阪 琢磨<sup>3</sup>

<sup>1</sup> 独立行政法人国立病院機構 大阪医療センター 薬剤科

<sup>2</sup> 独立行政法人国立病院機構 京都府病院 薬剤科

<sup>3</sup> 独立行政法人国立病院機構 大阪医療センター HIV/AIDS 先端医療開発センター

**目的:** ATV/r 服用患者を対象に, ATV の血中濃度が高値を示す患者を ATV<sub>400</sub> へ変更することにより, 有効性を維持しつつ, 副作用の軽減を図ることを目的に臨床試験を実施した。

**対象および方法:** 2004 年 6 月から 2008 年 5 月までの期間, 当院で ATV/r を服薬し, ATV のトラフ血中濃度が 1.50 μg/mL 以上の患者 5 例を対象とした。ATV<sub>400</sub> へ変更後 4, 8, 12, 16, 20, 24 週目にトラフ濃度, HIV-RNA 量, T-Bil, T-Cho, TG を測定し, Dunnett の多重解析法を用いて比較検討した。

**結果:** 対象患者 5 例の ATV トラフ濃度 (mean±S.D.) は, 1.95±0.39 μg/mL (range: 1.54-2.56) であった。変更後 4 週目 ATV トラフ濃度の平均値は 0.26±0.18 μg/mL (range: 0.10-0.52) に低下したが, HIV-RNA 量は臨床試験を実施した 24 週間を通じて, 全例感度未満を持続した。変更前後で, T-Bil, T-Cho は有意に低下した (p<0.05)。

**結論:** ATV トラフ濃度が 1.50 μg/mL 以上を示す患者が ATV<sub>400</sub> へ変更した場合の 24 週間における安全性と有効性が示唆された。T-Bil と T-Cho が変更後に有意に低下したことは, 黄疸の軽減と患者の QOL の向上につながり, 長期服用による副作用発現を未然に防止できたものと考えられた。

**キーワード:** HAART, ATV, RTV, 血中濃度, Bil

日本エイズ学会誌 11: 50-53, 2009

### 緒 言

硫酸アタザナビル (ATV) は, 米国で 2003 年 6 月に HIV 感染症の治療薬として承認されたプロテアーゼ阻害薬 (PI) であり, 1 日 1 回投与が可能な PI として, 米国 DHHS (Department of Health and Human Services) のガイドラインでは第一選択薬として推奨されている<sup>1)</sup>。ATV のヒトにおける主な代謝経路は, 一酸化及び二酸化反応であり, ヒト肝ミクロゾームを用いた *in vitro* 試験から, チトクローム P450 の分子種 CYP3A4 により代謝を受けることが確認されている<sup>2)</sup>。ATV と併用するリトナビル (RTV) は, CYP3A4 を強力に阻害することが知られており, 少量の RTV を併用することにより PI の効果を増強するブースト療法が一般的となっている<sup>3)</sup>。ブーストしない ATV 400 mg 投与 (ATV<sub>400</sub>) は, RTV 100 mg でブーストした ATV 300 mg 投与 (ATV/r) に比べ, トラフレベルの血中濃度 (トラフ濃度) が 87%, AUC が 51% 低下することが報告されてい

る<sup>2)</sup>。ATV/r では症例によって ATV の血中濃度の上昇が, Total Bilirubin (T-Bil) の上昇を惹起している可能性が示唆される。RTV は冷蔵保存が必要であることから, 患者の利便性に支障があり, RTV の相互作用上の併用注意薬も多く, 併用を避けざるを得ない症例も経験する。今回, ATV/r 服用患者において ATV のトラフ濃度が高値を示す患者に対し, ATV<sub>400</sub> へ変更することにより, 有効性を維持しつつ, 副作用の軽減を図ることを目的に臨床試験を実施した。なお本研究は, 国立病院機構大阪医療センターの倫理委員会に相当する受託研究審査委員会の承認を得た (承認番号: 0710)。

### 対象および方法

国立病院機構大阪医療センター免疫感染症科に通院し, 少なくとも 14 日間以上, ATV/r を含む HAART を施行し, ATV のトラフ濃度が 1.50 μg/mL 以上の患者で, 問診により血中濃度測定前 1 週間の服薬率が 100% と見込まれた患者に対し本研究の趣旨の説明を行い, 試験参加の同意を文書で得た 5 例を対象とした。併用した核酸系逆転写酵素阻害薬 (NRTI) は, 全例, アバカビル/ラミブジン合剤 (EZC) であった。同意取得後, ATV/r から ATV<sub>400</sub> へ変更

著者連絡先: 吉野宗宏 (〒540-0006 大阪府大阪市中央区法円坂 2-1-14 独立行政法人国立病院機構 大阪医療センター 薬剤科)

2008 年 9 月 26 日受付; 2009 年 1 月 20 日受理

を行った。対象となった患者の平均年齢 (mean±S.D.) は 46±12 歳 (33-63 歳) で、すべて男性であった。

なお、テノホビル (TDF) 並びに TDF 配合剤、プロトンポンプ阻害剤 (PPI)、高脂血症剤等、ATV 血中濃度に影響を及ぼすと考えられる薬剤の投与を受けている患者は本臨床試験の対象外とした。調査期間は 2004 年 6 月 1 日から 2008 年 5 月 31 日までとした。

血中濃度測定は以下の方法で行った。ヘパリンナトリウムを添加した試験管に、1 回 5 mL の血液を採取し、10°C 以下 3000 回転 10 分間遠心分離し、ポリプロピレン製のスクリューキャップ付きチューブに血漿を 2 mL 分注し、分析開始まで -80°C で凍結保存した。測定は HPLC 法を用い、株式会社積水メディカルで実施した。また、血中濃度測定は、厚生労働科学研究費補助金「抗 HIV 薬の血中濃度に関する臨床研究」により実施した。

ATV<sub>400</sub>へ変更後 4, 8, 12, 16, 20, 24 週目に採血を実施し、ATV のトラフ濃度、HIV-RNA 量、T-Bil、T-Cho、TG を測定し、ATV<sub>400</sub>への変更前後の 24 週間について比較検討を行った。T-Bil、T-Cho、TG については、変更前後の両群間の変動 (%) を Dunnett の多重分析法を用いて解析した。

## 結 果

対象患者の治療変更前後の血中濃度を表 1、臨床検査値を表 2 に示す。ATV トラフ濃度 (mean±S.D.) は 1.95±0.39 µg/mL (range : 1.54-2.56) であった。ATV<sub>400</sub>への変更

後 4 週目に、患者の ATV 血中濃度は 0.26±0.18 µg/mL (range : 0.10-0.52) に低下し、その後 24 週までほぼ一定の値を示した。HIV-RNA 量は臨床試験を実施した 24 週間を通じて、全例感度未満を持続していた。変更後の T-Bil の変動 (%) において 4, 20, 24 週に変更前に比べ有意な低下が認められた ( $p < 0.05$ )。また、T-Cho の変動 (%) は 12, 16, 20, 24 週に有意な低下が認められた ( $p < 0.05$ )。TG については変更後 4 週以降、16 週を除き、有意差は認められないものの低下傾向を示した。

## 考 察

PI のウイルス学的効果は血中濃度と相関することから<sup>4,5)</sup>、ウイルス学的有効性を考えれば、より高く血中濃度を維持することが出来る ATV/r の有効性は ATV<sub>400</sub> より勝っていると考えられる。しかし、ATV のトラフ濃度が高値となると T-Bil の上昇を惹起することが複数報告されている<sup>6,7)</sup>。また、ATV による T-Bil の上昇は、一般に肝機能障害とは関係なく<sup>8)</sup>、安全性に問題はないとされているが、黄疸という副作用症状は患者の外観の変化を来すことから、その発現する症状を嫌い、服薬変更を希望する場合や、患者によっては服薬の自己中断を行った症例も経験している。ATV の血中濃度は、有効かつ黄疸等の副作用が発現しない濃度でコントロールすることが最も望ましい。ブースタとして使用する RTV は冷蔵庫での保存が必要であり、患者にとっては利便性を阻害する要因の一つとなり、さらに RTV は相互作用のある薬剤も多いため、併用を避けざ

表 1 ATV trough plasma concentration (µg/mL)

| patient     | Baseline    | week 4      | week 8      | week 12     | week 16     | week 20     | week 24     |
|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| 1           | 1.54        | 0.10        | 0.10        | 0.16        | 0.15        | 0.17        | 0.41        |
| 2           | 1.72        | 0.23        | 0.16        | 0.15        | 0.16        | 0.16        | 0.13        |
| 3           | 2.03        | 0.35        | 0.23        | 0.29        | 0.24        | 0.31        | 0.15        |
| 4           | 1.90        | 0.11        | 0.42        | 0.20        | 0.28        | 0.10        | 0.10        |
| 5           | 2.56        | 0.52        | 0.59        | 0.20        | 0.36        | 0.69        | 0.35        |
| Mean (S.D.) | 1.95 (0.39) | 0.26 (0.18) | 0.30 (0.20) | 0.20 (0.06) | 0.24 (0.09) | 0.29 (0.24) | 0.23 (0.14) |

表 2 Laboratory parameters

| Parameter           | n | Baseline     | week 4       | Week 8       | week 12       | week 16       | week 20       | week 24       |
|---------------------|---|--------------|--------------|--------------|---------------|---------------|---------------|---------------|
| T-Bil (mg/dL)       | 5 | 3.46 (1.45)  | 1.56 (0.50)* | 2.14 (0.58)  | 2.04 (0.63)   | 1.86 (0.57)   | 1.43 (0.87)*  | 1.72 (0.29)*  |
| T-Cho (mg/dL)       | 5 | 205.6 (41.2) | 194.4 (45.9) | 185.2 (30.7) | 172.6 (29.8)* | 180.8 (39.6)* | 187.5 (25.2)* | 166.0 (35.0)* |
| TG (mg/dL)          | 5 | 259.4 (70.4) | 122.2 (44.9) | 134.2 (41.7) | 128.8 (71.0)  | 228.0 (103.8) | 128.8 (62.3)  | 120.2 (49.3)  |
| HIV-RNA (copies/mL) | 5 | <50          | <50          | <50          | <50           | <50           | <50           | <50           |

Data expressed as Mean (S.D.)

\* Significant difference from the baseline at  $p < 0.05$  using parametric Dunnett's multiple comparison test.

M Yoshino *et al* : Successful Switch from ATV/r to ATV 400 in HIV-infected Patients with High Plasma ATV Concentrations

るを得ない場合もある。従って、治療の有効性を高めるためには高い血中濃度を維持することは効果的であるが、高い血中濃度を示す患者に対し、ブースタである RTV の使用を中止し、ATV 400 mg 投与に変更し、その有用性を検討することは臨床的意義があると考えられる。

今回我々は、ATV/r 服用患者において ATV のトラフ濃度が  $1.50 \mu\text{g}/\text{mL}$  以上を示す患者に焦点を絞り、ATV<sub>400</sub> へ変更することで、有効性の維持と、副作用の軽減について検討した。対象患者のトラフ濃度を  $1.50 \mu\text{g}/\text{mL}$  以上にした設定根拠は、ATV/r を服用した健常成人が、ブーストしない ATV<sub>400</sub> へ変更した場合、トラフ濃度の幾何平均値が  $1.23 \mu\text{g}/\text{mL}$  から  $0.16 \mu\text{g}/\text{mL}$  へ 87%、AUC が  $57.0 \mu\text{g} \cdot \text{h}/\text{mL}$  から  $28.1 \mu\text{g} \cdot \text{h}/\text{mL}$  へ 51% 低下する報告に基づき<sup>2)</sup>、DHHS のガイドラインが推奨する ATV 目標トラフ濃度  $0.15 \mu\text{g}/\text{mL}$ <sup>1)</sup> を維持するためには、トラフ濃度が  $1.50 \mu\text{g}/\text{mL}$  以上必要であると推定した。

ATV/r から ATV<sub>400</sub> へ変更後、トラフ濃度の平均値は  $1.95 \pm 0.39 \mu\text{g}/\text{mL}$  から 4 週後には  $0.26 \pm 0.18 \mu\text{g}/\text{mL}$  まで約 86% 低下した。変更後の低下率は先の報告<sup>2)</sup> と類似しており、トラフ濃度の平均値は 24 週間において  $0.15 \mu\text{g}/\text{mL}$  以上を維持したことから、今回対象患者のトラフ濃度を  $1.50 \mu\text{g}/\text{mL}$  以上にした設定根拠は、妥当であると考えられる。しかし、表 1 に示すように、測定した患者の血中濃度には目標トラフ濃度を下回ったデータもあり、臨床試験を実施した 24 週間における患者の HIV-RNA 量は、全例検出限界未満を維持していたものの、長期の安全性を検討するための ATV/r 服用患者における ATV トラフ濃度の設定に関しては検討が必要と考える。

ATV<sub>400</sub> へ変更後、T-Bil が有意に低下したことは、黄疸の軽減と患者の QOL の向上につながった。HAART による高脂血症は、主に PI が関与しており、服用期間が長いほど虚血性心疾患の頻度が増加し、1 年の HAART への暴露で年間発生率が 26% 増加することが報告されている<sup>9,10)</sup> ことから、T-Cho、TG が変更後に低下したことは、長期服用による副作用発現を未然に防止できたものと考えられた。ATV のトラフ濃度が高値を示す患者に対し、ATV<sub>400</sub> へ変更した 24 週間における安全性と有効性が示唆された。今後、ATV/r から ATV<sub>400</sub> への変更について長期間の安全性と有効性を検討するためには、より多くの症例について長期間観察を行う臨床試験が必要である。

## 文 献

- 1) The Department of Health and Human Services : Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, revised on November 3, 2008.
- 2) Reyataz [patient information]. Princeton, NJ : Bristol-Myers Squibb. March 2008. Available at : [http://packageinserts.bms.com/pi/pi\\_reyataz.pdf](http://packageinserts.bms.com/pi/pi_reyataz.pdf). August, 2008.
- 3) Zeldin RK, Petruschke RA : Pharmacokinetic and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. *J Antimicrob Chemother* 53 : 4-9, 2004.
- 4) Acosta EP, Gerber JG and Adult Pharmacology Committee of the AIDS Clinical Trials Group : Position paper on therapeutic drug monitoring of antiretroviral agents. *AIDS Res Hum Retroviruses* 18 : 825-834, 2002.
- 5) Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, Del Giudice P, Montagne N, Schapiro JM, Dellamonica P : Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy : pharmacological data from the Viradapt Study. *AIDS* 14 : 1333-1339, 2000.
- 6) Ray JE, Marriott D, Bloch MT, McLachlan AJ : Therapeutic drug monitoring of atazanavir : surveillance of pharmacotherapy in the clinic. *Br J Clin Pharmacol* 60 : 291-299, 2005.
- 7) Smith DE, Jeganathan S, Ray J : Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. *HIV Clin Trials* 7 : 34-38, 2006.
- 8) Le Tiec C, Barrail A, Goujard C, Taburet AM : Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. *Clin Pharmacokinet* 44 : 1035-1050, 2005.
- 9) Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiébaud R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD : Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. *N Engl J Med* 349 : 1993-2003, 2003.
- 10) d'Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, El-Sadr W, De Wit S, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Lundgren JD, Friis-Moller N : Writing Committee of the D : A : D : Study Group. Cardio- and cerebrovascular events in HIV-infected persons. *AIDS* 18 : 1811-1817, 2004.

## Successful Switch from ATV/r to ATV 400 in HIV-infected Patients with High Plasma ATV Concentrations

Munehiro YOSHINO<sup>1</sup>, Hiroki YAGURA<sup>1</sup>, Takeshi KUWAHARA<sup>2</sup>, Hiroki BANDO<sup>3</sup>, Yoshihiko OGAWA<sup>3</sup>, Keishiro YAJIMA<sup>3</sup>, Tomohiro TANIGUCHI<sup>3</sup>, Naruhito OTANI<sup>3</sup>, Shinjiro TOMINARI<sup>3</sup>, Dai WATANABE<sup>3</sup>, Tomoko UEHIRA<sup>3</sup> and Takuma SHIRASAKA<sup>3</sup>

<sup>1</sup> Department of Pharmacy, National Hospital Organization Osaka National Hospital

<sup>2</sup> Department of Pharmacy, National Hospital Organization Minami Kyoto National Hospital

<sup>3</sup> AIDS Medical Center, National Hospital Organization Osaka National Hospital

**Objectives** : We examined the changeover to atazanavir 400 mg (ATV 400) in patients taking atazanavir/ritonavir (ATV/r) with high plasma ATV concentrations, with the goal of reducing adverse effects, while maintaining efficacy.

**Subjects and Methods** : The subjects were five patients taking ATV/r at our hospital between June 2004 and May 2008 who had ATV trough plasma concentrations of 1.50 µg/mL or more. The trough plasma concentration, HIV-RNA level, total bilirubin (T-Bil), total cholesterol (T-Cho), and triglycerides (TG) were measured 4, 8, 12, 16, 20, and 24 weeks after switching to ATV 400 and the results were compared using Dunnett's multiple analysis.

**Results** : The ATV trough concentration of the five patients averaged  $1.95 \pm 0.39$  µg/mL (mean  $\pm$  S.D. ; range 1.54 to 2.56 µg/mL). Four weeks after the switchover, it had declined to  $0.26 \pm 0.18$  µg/mL (range 0.10 to 0.52 µg/mL), while the HIV-RNA levels in all cases were maintained below the detection level of 50 copies/mL at 24 weeks. After the switchover, T-Bil and T-Cho declined significantly ( $p < 0.05$ ).

**Conclusions** : It appears safe and effective to switch patients with ATV trough concentrations of 1.50 µg/mL and above to ATV 400. The significant declines in T-Bil and T-Cho after the switchover were linked to the decline in jaundice and improved quality of life (QOL) of the patients. It was thought that the adverse effects caused by taking ATV/r for a prolonged period were prevented.

**Key words** : HAART, atazanavir, ritonavir, pharmacokinetics, bilirubin

研究分担者 南 留美

## 1. 論文発表

1. High molecular weight form of adiponectin in antiretroviral drug-induced dyslipidemia in HIV-infected Japanese individuals based on in vivo and in vitro analyses. Minami R, Yamamoto M, Takahama S, Ando H, Miyamura T, Suematsu E. *Intern Med.* 2009;48(20):1799-875, 2009
2. Human herpesvirus 8 DNA load in the leukocytes correlates with the platelet counts in HIV type 1-infected individuals. Minami R, Yamamoto M, Takahama S, Ando H, Miyamura T, Suematsu E. *AIDS Res Hum Retroviruses.*;25(1):1-8, 2009.
3. 治療後ウエスタンプロット法にて抗 HIV 抗体が陰性化し持続している HIV-1 感染症の一例。南留美、高濱宗一郎、安藤仁、山本政弘、日本感染症学誌 83 巻 3 号、p251-5, 2009
4. 南 留美, HAART による脂質代謝異常と高分子アディポネクチンの関連, *Focus on HIV/AIDS*, 2008

## 2. 学会発表

1. The effect of antiretroviral drug on the lipid metabolism in hepatocytes with and without HCV infection. Minami R, Takahama S, Ando H, Yamamoto M. 9th International Congress on AIDS in Asia and the Pacific (ICAAP), in Bali, Indonesia from 9-13 August 2009.
2. Increasing Prevalence of Drug-resistance Mutations among Treatment-naïve HIV-infected Patients in Japan, 2003 to 2007. Junko Hattori<sup>\*1</sup>, S Yoshida<sup>2</sup>, H Gatanaga<sup>3</sup>, M Kondo<sup>4</sup>, K Sadamasu<sup>5</sup>, T Shirasaka<sup>6</sup>, H Mori<sup>4</sup>, R Minami<sup>7</sup>, W Sugiura<sup>1,8</sup>, and the Japanese Drug Resistance HIV-1 Surveillance Network. The 16th Conference on Retroviruses and Opportunistic Infections. February 8 - 11, 2009, Montreal, Canada
3. High molecular weight form of adiponectin in antiretroviral drug-induced dyslipidemia based on in vivo and in vitro analyses. Minami R, Takahama S, Ando H, Yamamoto M, XVII International AIDS Conference, 3-8 August, 2008, Mexico City
4. 2003-2008 年の新規 HIV/AIDS 診断症例における薬剤耐性頻度の動向. 服部順子、湯. 永博之、吉田繁、(略)、南留美、山本政弘、(略)、杉浦互, 第 23 回日本エイズ学会学術集会 2009 年 11 月 26-28 日、名古屋
5. 多施設共同疫学調査における HAART の有効率 菊池嘉、岩本愛吉、佐藤典宏、伊藤俊広、田邊嘉也、横幕能行、上田幹夫、渡邊大、藤井輝久、南留美、宮城島拓人、建山正男, 第 23 回日本エイズ学会学術集会 2009 年 11 月 26-28 日、名古屋

6. 抗 HIV 剤は HBV 感染肝細胞における肝脂質代謝を促進する. 南留美、高濱宗一郎、安藤仁、山本政弘. 第 23 回日本エイズ学会学術集会 2009 年 11 月 26-28 日、名古屋
7. RAL/ATV/RTV によるダブルブースト療法が奏効した吸収不良 HIV 感染症の 1 例, 高濱宗一郎、安藤仁、南留美、山本政弘, 第 23 回日本エイズ学会学術集会 2009 年 11 月 26-28 日、名古屋
8. 福岡地域における HIV 感染者および AIDS 患者から分離された HIV の遺伝子解析川本大輔、桶脇弘、高橋真梨子、南留美、山本政弘, 第 23 回日本エイズ学会学術集会 2009 年 11 月 26-28 日、名古屋
9. スポンサーシップシンポジウム「「当院における Raltegravir の使用経験 臨床的および in vitro での解析」南留美
10. 第 23 回日本エイズ学会学術集会 2009 年 11 月 26-28 日、名古屋、「HIV 感染に関する 3 つの話」南留美、第 7 回福岡 HIV 感染症治療研究会 2009 年 11 月 6 日
11. 抗 HIV 剤の肝細胞, HCV 感染肝細胞における脂質代謝への影響, 南留美、高濱宗一郎、安藤仁、山本政弘, 第 22 回日本エイズ学会, 11 月 26-28 日, 大阪
12. プロテアーゼ阻害剤が骨代謝に及ぼす影響, 高濱宗一郎, 南留美, 安藤仁, 山本政弘, 第 22 回日本エイズ学会, 11 月 26-28 日, 大阪
13. 社会的背景の複雑な患者の退院調整を振り返って一発達遅滞の患者の一事例を通じて一, 長与由紀子, 城崎真弓, 辻麻理子, 本松由紀, 首藤美奈子, 安藤仁, 南留美, 山本政弘, 第 22 回日本エイズ学会, 11 月 26-28 日, 大阪
14. 2003-2007 年の新規 HIV-1 感染者における薬剤耐性頻度の動向, 杉浦互, 瀧永博之, 吉田繁, 南留美, 山本政弘ら, 第 22 回日本エイズ学会, 11 月 26-28 日, 大阪
15. サルモネラ菌血症による感染性腹部大動脈瘤を合併した HIV 感染症の一例, 安藤仁, 南留美, 高濱宗一郎, 山本政弘, 第 82 回日本感染症学会総会, 2008 年 4 月 18-19 日, 松江



# Human Herpesvirus 8 DNA Load in the Leukocytes Correlates with the Platelet Counts in HIV Type 1-Infected Individuals

Rumi Minami, Masahiro Yamamoto, Soichiro Takahama, Hitoshi Ando,  
Tomoya Miyamura, and Eiichi Suematsu

## Abstract

Human herpes virus 8 (HHV-8) is known to be reactivated in immunocompromised situations and it is associated with Kaposi's sarcoma (KS) and some hematological diseases. The aim of this study was to analyze the effect of HHV-8 on HIV-1 infection, especially on thrombocytopenia complicated with HIV infection. The HHV-8 DNA load was determined by a quantitative real-time PCR, using leukocytes from 125 HIV-1-infected individuals. HHV-8 DNA was detected in 37 individuals. The increased HIV-1 load and reduced percentage of CD4-positive T cells were significantly associated with the presence of HHV-8. The prevalence and load for HHV-8 are higher in patients with KS than in patients without KS, but the difference is not significant. The increased HHV-8 DNA load was significantly correlated with thrombocytopenia, and platelet counts were significantly lower in individuals with HHV-8 than in individuals without HHV-8. We also obtained the negative correlations between changes in platelet counts and changes in HHV-8 DNA loads. The association between thrombocytopenia and HHV-8 has never been reported previously, apart from some case reports of Castleman's disease and KS. Various cytokines or chemokines are produced by HHV-8-infected cells, some of which have been reported to inhibit hematopoiesis. This may be one of the mechanisms by which HHV-8 infection induces thrombocytopenia. These results indicate that HHV-8 DNA in leukocytes may provide useful information for the assessment of the clinical appearance of HIV-1 infection.

## Introduction

HHV-8, A NEW MEMBER OF THE GAMMAHERPESVIRINAE, was identified as the etiologic agent of Kaposi's sarcoma (KS). The main transmission routes of human herpes virus 8 (HHV-8) seem to be sexual contact,<sup>1</sup> but transmission by saliva,<sup>2</sup> blood products, and organ graft<sup>3,4</sup> has also been proposed. The distribution of HHV-8 is related to a combination of geographic and behavioral risk factors. Serological studies have shown that HHV-8 seroprevalence is high in Africa and the Middle East and low in Europe and the United States. In Japan, it is reported that HHV-8 seroprevalence among healthy controls is 0.2–1.4% and HHV-8 seroprevalence among HIV-1-positive homosexual men is 11.6–63.6%.<sup>5,6</sup>

HHV-8 can infect circulating B cells, monocytes, macrophages, T cells, and KS-like spindle cell progenitors,<sup>7–9</sup> and usually persists in a latent state in these cells. The reactivation of this latent HHV-8 infection can be induced by a number of conditions, including superinfection by other viruses, stress, chronic illnesses, malignancies, and immunosuppressive disorders, such as HIV infection. HHV-8 contains more than

80 open reading frames, including several homologues of oncogenes, cytokine, and cytokine response genes. During latent and lytic infection, some viral genes are expressed and play a causative role in the genesis of some diseases, such as AIDS and non-AIDS-related KS, multicentric Castleman's disease, body cavity-based lymphoma, and some lymphoproliferative diseases. Our previous study reported a case of Castleman's disease with HIV-1 infection in which repeated episodes of thrombocytopenia were correlated with an increase in HHV-8 DNA loads in leukocytes.<sup>10</sup> The aim of this study was to determine the prevalence and loads of HHV-8 DNA in peripheral blood leukocytes in HIV-1-positive individuals and to investigate the correlation with the clinical appearance of HIV-1 infection, especially with thrombocytopenia.

## Materials and Methods

### Patients and samples

All consecutive HIV-1-infected patients who attended Kyushu Medical center between April 2005 and August 2006

were eligible for this study. The exclusion criteria were HCV infection, active hepatitis, and treatment for antihyperthermia at the time of sampling. Nine HIV-1-positive individuals were analyzed longitudinally before and after the initiation of antiretroviral therapy (ART). For controls, 12 HIV-1-seronegative patients with autoimmune thrombocytopenia and 17 HIV-1-seronegative healthy volunteers were sampled for baseline comparisons. Informed consent for blood sampling was obtained from all participants. The study was conducted according to the ethical guidelines of the hospital and was approved by an authorized representative of the hospital. EDTA-treated blood was taken from the subjects, and leukocytes were collected after removing red blood cells with hemolysis buffer (155 mM NH<sub>4</sub>Cl, 10 mM KHCO<sub>3</sub>, 0.1 mM EDTA). Cell pellets were stored at -20°C until use.

### Real-time quantitative PCR

DNA was extracted from the cell pellets using a QIAamp Blood Mini kit (QIAGEN Inc., Tokyo, Japan). Real-time PCR was conducted with the LineGene33 (BioFlux, Tokyo, Japan) using Premix Ex Taq (TAKARA, Shiga, Japan). As an internal control measurement, to normalize for input DNA, copy numbers of  $\beta_2$ -microglobulin ( $\beta_2$ M) were determined in every sample tested. The primers used for amplification were as follows: HHV-8 forward, 5'-CCTCTGGTCCCCATTCATG-3', and reverse, 5'-CGTTTCCGTCGTGGATGAG-3', and probe 5'-FAM-CCGGCGTCAGACATTCTCACAAACC-TAMRA-3';<sup>11</sup> Epstein-Barr virus (EBV) forward, 5'-CGGAAGCCCTCTGGA CTC-3', and reverse, 5'-CCCTGTTATCCGATGGAATG-3', and probe 5'-FAM-TGTACACGCACGAGAAATGCGCC-TAMRA-3';<sup>12</sup>  $\beta_2$ M forward, 5'-CAGCAAGGACTGGTCTTT CTATCTCT-3', and reverse, 5'-ACCCCACTTAACTATCTT GG-3', and probe 5'-FAM-CACTGAAAAAGATGAGTATG CCTGCCGTGT-TAMRA-3'.<sup>13</sup> Standards were obtained by amplification of a control sample in a polymerase chain reaction (PCR) reaction using the same primers. The data were normalized as copies/10<sup>6</sup> cells by measuring copy numbers of the  $\beta_2$ M gene, since two  $\beta_2$ M copy numbers correspond to one cell. The lower limit of detection was defined as 1 copy/10<sup>6</sup> cells.

### Statistical analyses

Frequency analysis was performed using Fisher's exact test for 2×2 tables. The viral DNA copy numbers of HHV-8, EBV, and HIV-1 were log<sub>10</sub> transformed and compared between different groups by means of the Mann-Whitney *U* test. The associations between them were determined using an analysis of covariance (ANCOVA), with EBV-DNA and HIV-RNA as covariates, where HHV-8 DNA was adjusted on the bases of

EBV-DNA and HIV-RNA. Spearman's rank correlation coefficient was used to compare changes in platelet counts and changes in HHV-8 DNA loads. A partial correlation was used to assess this relationship, while controlling for any changes in HIV-RNA and EBV-DNA.

## Results

### Subjects characteristics

A total of 125 patients fulfilled the inclusion criteria. Demographic and clinical characteristics of the subjects included in this study are shown in Table 1. There were 8 women and 117 men, 112 of whom were men who have sex with men; the others were heterosexual. These patients were ranged from 20 to 69 years of age (mean age, 37.8 years). Of these, 58 received ART and 67 remained untreated. The duration of ART was 3 months to 9.5 years (mean 3.25 years). Nine HIV-1-positive individuals were analyzed longitudinally before and after the initiation of ART. Among 125 HIV-1-positive subjects included in our study, we evaluated 97 subjects for the prevalence of splenomegaly by means of an abdominal ultrasound examination; 23 subjects were thus found to have splenomegaly.

### HHV-8 qualitative and quantitative DNA analysis

The presence and load of HHV-8 DNA were investigated in 125 HIV-1-positive subjects and 17 HIV-1-negative healthy controls (Fig. 1). HHV-8 DNA was detected in 37 of 125 (29.6%) leukocyte samples from HIV-1-positive subjects, with values ranging from 2 to 91,171 copies/10<sup>6</sup> leukocytes. HHV-8 DNA was not detected in any healthy controls.

### Relationship between HHV-8 DNA and KS

HHV-8 DNA was detected in three of five (60%) HIV-infected subjects with KS, whereas they were found in 34 of 120 (28.3%) subjects without KS ( $p=0.15$ ). Figure 2 shows that the HHV-8 DNA load of subjects with KS to be higher than that of the subjects without KS, but not significantly so.

### The correlation between HHV-8 DNA and HIV-1-related immunovirological parameters

The HIV-RNA load in the serum of HHV-8 DNA-positive subjects was significantly higher than that of HHV-8 DNA-negative subjects (Fig. 3a). In addition, the correlation between HHV-8 DNA and hypergammaglobulinemia (the percentage of gammaglobulin is more than normal range) was examined, which is often observed in HIV-1-positive subjects. The HHV-8 DNA load in leukocytes in subjects with

TABLE 1. DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF 125 HIV-POSITIVE SUBJECTS<sup>a</sup>

|   | Total       | Pretreatment of ART | Treatment of ART      | p      |
|---|-------------|---------------------|-----------------------|--------|
| N (male/female)                             | 125 (117/8) | 67 (63/4)           | 58 (54/4)             |        |
| Age (years)                                 | 37.8 ± 10.4 | 34.3 ± 8.2          | 42.1 ± 11.2           | <0.001 |
| CD4 (cells/ml)                              | 396 ± 218   | 387 ± 226           | 407 ± 211             | 0.616  |
| Viral load (copies/ml) (log <sub>10</sub> ) |             | 4.36 ± 0.86         | Under detection limit |        |
| Duration of ART (years)                     |             | 0                   | 3.25 ± 2.68           |        |

<sup>a</sup>The mean values ± SE are shown. Pretreatment of ART versus treatment of ART.

## HHV-8 AND THROMBOCYTOPENIA IN HIV-1 INFECTION

3




FIG. 1. Quantification of HHV-8 DNA by real-time PCR. Log<sub>10</sub>-transformed HHV-8 copy numbers per 10<sup>6</sup> leukocytes are shown. The bar shows the mean and standard deviations. The dotted line shows the detection limit of the assay.

hypergammaglobulinemia was significantly higher than in subjects without hypergammaglobulinemia (Fig. 3b). HHV-8 DNA was detected in 24 of 44 (54.5%) HIV-infected subjects with hypergammaglobulinemia, whereas it was found in 13 of 81 (16.0%) subjects without hypergammaglobulinemia ( $p < 0.0001$ ). We could not find any significant correlation between HHV-8 DNA loads and CD4-positive T cell counts.

#### The effect of ART on HHV-8 DNA

HHV-8 DNA load in leukocytes in subjects with ART was significantly lower than in subjects without ART (Fig. 4a). HHV-8 DNA was detected in 12 of 58 (20.7%) HIV-infected subjects with ART, whereas it was found in 25 of 67 (37.3%) subjects without ART ( $p = 0.042$ ). There was no difference in the duration of ART between HHV-8 DNA-negative and HHV-8 DNA-positive subjects with ART ( $3.161 \pm 2.764$  vs.  $3.575 \pm 2.439$  years,  $p = 0.624$ ). HHV-8 DNA loads ( $\log_{10}$ ) per 10<sup>6</sup> leukocytes in subjects with a short duration of ART (<6 months) were higher than in subjects with a long duration of ART ( $\geq 6$  months), but the difference was not statistically significant ( $0.758 \pm 0.447$  vs.  $0.323 \pm 0.111$ ,  $p = 0.309$ ).




FIG. 2. HHV-8 DNA loads among the HIV-1-positive subjects with or without KS. Log<sub>10</sub>-transformed HHV-8 copy numbers per 10<sup>6</sup> leukocytes are shown. The bar shows the mean and standard deviations.  $p$ -values were estimated by the Mann-Whitney  $U$  test. The dotted line shows the detection limit of the assay.

#### Longitudinal analysis of HHV-8 DNA loads after initiation of ART


The longitudinal profiles of HHV-8 DNA loads were examined in nine subjects after initiation of ART (Fig. 4b). Within 1 month after starting ART, HHV-8 DNA transiently increased in three patients (Fig. 4b, black straight lines); in two of the three patients, KS had progressed transiently. These findings show the reactivation of HHV-8 by initiation of ART. Three months after the initiation of ART, all nine patients had achieved and maintained the decreased levels of HHV-8 DNA.

#### The influence of EBV on HHV-8 infection

Like HHV-8, EBV is lymphotropic and is a member of the gammaherpesvirinae; it is reactivated by HIV-1 infection. Therefore, the influence of EBV on HHV-8 infection was investigated. EBV-DNA loads ( $\log_{10}$ ) per 10<sup>6</sup> leukocytes were significantly higher in HHV-8 DNA-positive subjects ( $0.69 \pm 0.11$  vs.  $1.46 \pm 0.21$ ,  $p = 0.0007$ ) and EBV DNA was detected in 32 of 88 (36.4%) HHV-8-negative subjects, whereas they were found in 25 of 37 (67.5%) HHV-8-positive subjects ( $p = 0.002$ ).

#### Relationship between HHV-8 DNA and thrombocytopenia

Figure 5 shows a case of Castleman's disease in which the platelet counts changed in inverse association with HHV-8 DNA in the leukocytes. Therefore, the association between platelet counts and HHV-8 DNA in leukocytes was examined. First, the changes in platelet counts and HHV-8 DNA were analyzed in the nine subjects before and after the initiation of ART (Fig. 6). Both the decrease in HHV-8 DNA and the




**FIG. 3.** The correlation between HHV-8 DNA and HIV-1-related immunovirological parameters. (a) HIV-RNA loads among the HIV-1-positive subjects with or without HHV-8 DNA. Log<sub>10</sub>-transformed HIV-1 copy numbers/ml of serum are shown. The bar shows the mean and standard deviation. *p*-values were estimated by the Mann-Whitney *U* test. (b) HHV-8 DNA loads among the HIV-1-positive subjects with or without hypergammaglobulinemia. HHV-8 copy numbers per  $10^6$  leukocytes are shown. The bar shows the mean and standard deviations. *p*-values were estimated by the Mann-Whitney *U* test. The dotted line shows the detection limit of the assay.

increase in platelet counts were significant. Furthermore, the correlation between changes in platelet counts and changes in HHV-8 DNA was obtained (Spearman;  $r = -0.783$ ,  $p = 0.0267$ ). Patients with HIV infection sometimes develop thrombocytopenia, and EBV is also reported to cause mild thrombocytopenia. Therefore, partial correlations were also used

to assess this relationship while controlling for EBV-DNA and HIV-RNA, and the correlation between the change in HHV-8 DNA and platelet counts was obtained (partial correlation coefficient;  $r = -0.733$ ,  $p = 0.0219$ ).

Next, all 125 subjects with HIV infection were analyzed. There was no significant difference between the group with



**FIG. 4.** The effect of ART on HHV-8 DNA. (a) HHV-8 DNA load in PBMCs in subjects with or without ART. HHV-8 copy numbers per  $10^6$  leukocytes are shown. The bar shows the mean and standard deviation. *p*-values were estimated by the Mann-Whitney *U* test. (b) HHV-8 DNA load after initiation of ART. HHV-8 DNA loads of the nine subjects were measured at the indicated time points. The dotted line shows the detection limit of the assay.

## HHV-8 AND THROMBOCYTOPENIA IN HIV-1 INFECTION

5




FIG. 5. Time course of the case of Castleman's disease with HIV-1 infection. Platelet counts,  $\log_{10}$ -transformed HHV-8 and EBV copy numbers per  $10^6$  leukocytes, and  $\log_{10}$ -transformed HIV-1 copy numbers/ml of serum are shown. The data were excerpted from Minami and Yamamoto.<sup>10</sup> PLT, platelet; HHV-8, human herpes virus 8; EBV, Epstein-Barr virus; 3TC, lamivudine; ABC, abacavir; ATV, atazanavir.

thrombocytopenia and the group without thrombocytopenia in terms of the number of subjects with ART, the duration of ART, and the prevalence of subjects with splenomegaly (with thrombocytopenia vs. without thrombocytopenia; 30.8% vs. 22.6%,  $p = 0.520$ ). Similarly, no significant difference was observed between the group with HHV-8-DNA and the group without HHV-8-DNA in terms of the duration of ART and the prevalence of subjects with splenomegaly (with HHV-8 vs. without HHV-8; 26.7% vs. 22.4%,  $p = 0.647$ ). The effects of

HHV-8 DNA in leukocytes on platelet counts were examined using ANCOVA, with EBV-DNA as a covariate. ANCOVA revealed a significant interaction between EBV-DNA and HHV-8 DNA but no significant interaction between thrombocytopenia and EBV-DNA. Post hoc tests revealed that HHV-8 DNA was significantly higher in subjects with platelet counts  $<150,000$  platelets/ $\mu\text{l}$  than in subjects with platelet counts  $\geq 150,000$  platelets/ $\mu\text{l}$  (Fig. 7a). HHV-8 DNA was detected in 11 of 14 (78.6%) subjects with low platelet counts,





FIG. 6. Changes in the platelet counts, HHV-8 DNA loads, EBV-DNA loads, and HIV-RNA of pre- and post-ART. Platelet counts (a), HHV-8-DNA (b), EBV-DNA (c), and HIV-RNA (d) of the nine subjects were analyzed before (pre) and after 2 or 3 months of initiation of ART (post). The viral loads were  $\log_{10}$  transformed. Bar shows the mean and standard deviation.  $p$ -values for the difference between the two time points were estimated by the Wilcoxon signed rank test.



**FIG. 7.** Relationship between HHV-8 DNA and mild thrombocytopenia. (a) HHV-8 DNA load in leukocytes in subjects with platelet counts of  $<150,000$  platelets/ $\text{mm}^3$  or with platelet counts of  $\geq 150,000$  platelets/ $\text{mm}^3$ . HHV-8 copy numbers per  $10^6$  leukocytes are shown. The bar shows the mean and standard deviation. The  $p$ -values were estimated by a post hoc test after ANCOVA with EBV-DNA as a covariate. (b) Platelet counts among the HIV-1-positive subjects with or without HHV-8 DNA. The bar shows the mean and standard deviation. The  $p$ -values were estimated by a post hoc test after ANCOVA with EBV-DNA as a covariate. The dotted line shows the detection limit of the assay.

whereas it was found in 26 of 111 (23.4%) of subjects with normal platelet counts ( $p=0.0059$ ; estimated by post hoc test after ANCOVA with the prevalence of EBV-DNA as a covariate). The platelet counts were lower in HHV-8 DNA-positive subjects than in HHV-8 DNA-negative subjects, but not significantly (Fig. 7b). In subjects without ART, HIV-RNA might be a confounding factor, and thus ANCOVA was conducted with HIV-RNA and EBV-DNA as covariates.

In subjects without ART, HHV-8 DNA was also significantly higher in subjects with mild thrombocytopenia with an adjustment for EBV-DNA and HIV-RNA ( $p=0.013$ , data not shown). HHV-8 DNA was not detected in the 12 subjects with autoimmune thrombocytopenia. We also examined the correlation between HHV-8 DNA loads and platelet counts in subjects without KS, because the subject with KS might have occult Castleman's disease, which can cause thrombocytopenia. HHV-8 DNA was significantly higher in subjects with platelet counts of  $<150,000$  platelets/ $\mu\text{l}$  than in subjects with platelet counts of  $\geq 150,000$  platelets/ $\mu\text{l}$  [ $\log_{10}$  (HHV-8) =  $2.103 \pm 1.797$  vs.  $0.438 \pm 0.924$ ;  $p=0.0285$ ]. HHV-8 DNA was detected in 9 of 12 (75.0%) subjects with low platelet counts, whereas it was found in 25 of 108 (23.1%) subjects with normal platelet counts ( $p=0.0002$ ). The platelet counts were significantly lower in HHV-8 DNA-positive subjects than in HHV-8 DNA-negative subjects ( $21.5 \pm 8.61/\mu\text{l}$  vs.  $25.0 \pm 5.56/\mu\text{l}$ ;  $p=0.1319$ ).

## Discussion

Some previous studies have examined the prevalence of HHV-8 infection in HIV-1-infected subjects. A unique aspect of this study is that the effect of HHV-8 DNA in the peripheral

blood leukocytes on HIV-1 infection was examined; a significant association between HHV-8 DNA and the clinical appearance of HIV-1 infection, especially thrombocytopenia complicated with HIV-1, was found.

Some reports have shown that the presence of KS was associated with the prevalence of HHV-8 DNA in leukocytes<sup>14</sup> and the severity was associated with HHV-8 DNA loads in leukocytes.<sup>15</sup> The current data also showed a certain association with the presence of KS and HHV-8 DNA load, but in this study there were only five subjects with KS, because the prevalence of KS in HIV-1-infected patients in Japan is low. As a result, it was impossible to determine whether the HHV-8 DNA load predicted the onset and severity of KS. To draw any conclusions concerning the clinical and prognostic utility on KS, more subjects with KS need to be analyzed.

HHV-8 encodes homologues of cytokine and cytokine response genes, such as viral interleukin-6 (vIL-6)<sup>16</sup> and viral interferon regulatory factor (vIRF). vIL-6 can bind the gp130 receptor to activate IL-6 response genes and promote B cell activation, which is the mechanism of hypergammaglobulinemia induced by HHV-8 infection. It was also found that HHV-8 plays an important role in hypergammaglobulinemia, which is often found in subjects with HIV-1 infection.

The current data showed that HIV-RNA load in the serum of HHV-8 DNA-positive subjects was significantly higher than that found in the serum of HHV-8 DNA-negative subjects. HHV-8 replication is activated by HIV-Tat,<sup>17</sup> and it has been reported that HHV-8 reactivation is associated with HIV-1 acute infection.<sup>18</sup> Furthermore, an open reading frame (ORF), the major transactivator of the HHV-8 lytic cycle, can also induce increased levels of HIV replication. In conclusion, these findings show that HHV-8 coinfection is associated with

## HHV-8 AND THROMBOCYTOPENIA IN HIV-1 INFECTION

7

immunological characteristics and disease severity of HIV infection.

ART reduced HHV-8 DNA loads as well as HIV-RNA (Fig. 4). The inhibition of HIV-1 replication with ART probably leads to the reconstitution of the immune system and regenerates effective immune responses against HHV-8. Moreover, protease inhibitors block the production of inflammatory cytokines,<sup>19</sup> which in turn may result in the downregulation of HHV-8 replication. In this longitudinal study during ART, HHV-8 DNA loads transiently increased in three subjects soon after the initiation of ART. This might be due to the disorder of cytokine balance, which occurs transiently in the process of the reconstitution of the immune system, and this might be one of the explanations for the immune reconstitution syndrome of KS. Some inflammatory cytokines are induced in immune reconstitution syndromes. It has recently been reported that some cytokines, which are associated with the development of KS, were elevated in other reconstitution syndromes.<sup>20</sup> It is possible that reactivation of HHV-8 by ART might activate the inflammation of the other reconstitution syndromes by the increase in vIL-6 or other cytokines.

The difference between HHV-8 DNA in the subjects with platelet counts of <150,000 platelets/ $\mu$ l and in the subjects with platelet counts of  $\geq$ 150,000 platelets/ $\mu$ l was significant, but the difference between the platelet counts in the HHV-8 DNA-positive subjects and the platelet counts in the HHV-8 DNA-negative subjects was not significant. This is because HHV-8 DNA correlates with "mild" thrombocytopenia.

This is the first report that analyzed the association between HHV-8 DNA and thrombocytopenia in HIV-1-infected subjects, though there are a few studies that showed the relationship between HHV-8 infection and hematological disorders<sup>21</sup> or posttransplantation bone marrow failure in HIV-1-negative subjects.<sup>22</sup> Some case reports have described thrombocytopenia complicated with HHV-8-induced Castleman's disease, hemophagocytic syndrome, or other inflammatory syndromes. The HIV-1-positive subjects sometimes develop thrombocytopenia, which has been thought to be caused by an autoimmune mechanism. Recently, antibody cross-reactivity between a known epitope region of HIV-1 proteins and platelet GPIIIa49-66 has been reported to be responsible for HIV-1-associated thrombocytopenia.<sup>23</sup> However, the present study showed that HHV-8 also contributes independently to the thrombocytopenia complicated in HIV-1 infection.

The molecular mechanism of thrombocytopenia induced by HHV-8 remains to be established, but it is possible that some cytokines or chemokines induced by HHV-8 might be involved in thrombocytopenia. For example, interleukin-8 (IL-8), which is induced by HHV-8 infection,<sup>24</sup> binds the receptors on megakaryocytes and platelets and inhibits megakaryocytopoiesis.<sup>25</sup> Furthermore, HHV-8 is reported to infect CD34-positive hematopoietic progenitor cells<sup>26,27</sup>; HHV-8 harboring CD34-positive cells might also contribute to hematological disorders including thrombocytopenia.<sup>28</sup> Another possible explanation for thrombocytopenia is an autoimmune mechanism such as immune thrombocytopenia (ITP). Chronic stimulation of the B cell clones induced by HHV-8 could favor the production of autoantibodies, some of which might react against platelet. In fact, Evan's syndrome complicating multicentric Castleman's disease<sup>29</sup> and ITP complicating KS have been reported.<sup>30</sup>

In Italy, the area of subendemicity of HHV-8, the presence of HHV-8 DNA in HIV-1-negative elderly people has been reported to be associated with mild thrombocytopenia.<sup>31</sup> In Japan, HHV-8 infection in HIV-1-negative subjects is rare; as a result, when the 12 subjects with autoimmune thrombocytopenia were examined, the association between HHV-8 and autoimmune thrombocytopenia in HIV-1-negative subjects was not distinct. However, the fact that HHV-8 DNA was not detected in the HIV-1-negative subjects with autoimmune thrombocytopenia suggests that HHV-8 is not a main causative agent of autoimmune thrombocytopenia.

In conclusion, a significant association was observed between HHV-8 infection and the clinical appearance of HIV-1 infection, especially in regard to mild thrombocytopenia, hypergammaglobulinemia, and disease severity. It is possible that some of these effects of HHV-8 infection are related to other independent etiological cofactor or some other viruses. However, it may be useful to monitor HHV-8 DNA in leukocytes of HIV-1-positive subjects to assess and predict disease severity and to select the optimal treatment modalities.

## Acknowledgments

We are grateful to Ms. Asuka Horita and Ms. Mariko Takahashi for their

valuable technical support. This study was partly supported by Health Science Research Grants on HIV/AIDS from the Ministry of Health, Labor, and Welfare of the Japanese Government. The sponsor had no role in the study design, data collection, data analysis, and data interpretation, or in the writing of this report.

## Disclosure Statement

No competing financial interests exist.

## References

1. Ablashi DV, Chatlynne LG, Whitman JE Jr, and Cesarman E: Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. *Clin Microbiol Rev* 2002; 15:439-464.
2. Miller CS, Berger JR, Mootoor Y, Avdiushko SA, Zhu H, and Kryscio RJ: High prevalence of multiple human herpesviruses in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy. *J Clin Microbiol* 2006;44:2409-2415.
3. Challine D, Roudot-Thoraval F, Sarah T, *et al.*: Seroprevalence of human herpes virus 8 antibody in populations at high or low risk of transfusion, graft, or sexual transmission of viruses. *Transfusion* 2001;41:1120-1125.
4. Stein L, Carrara H, Norman R, Alagiozoglou L, Morris L, and Sitas F: Antibodies against human herpesvirus 8 in South African renal transplant recipients and blood donors. *Transpl Infect Dis* 2004;6:69-73.
5. Fujii T, Taguchi H, Katano H, *et al.*: Seroprevalence of human herpesvirus 8 in human immunodeficiency virus 1-positive and human immunodeficiency virus 1-negative populations in Japan. *J Med Virol* 1999;57:159-162.
6. Katano H, Iwasaki T, Baba N, *et al.*: Identification of antigenic proteins encoded by human herpesvirus 8 and seroprevalence in the general population and among patients with and without Kaposi's sarcoma. *J Virol* 2000;74:3478-3485.

7. Mesri EA, Cesarman E, Arvanitakis L, *et al.*: Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus is a new transmissible virus that infects B cells. *J Exp Med* 1996;183:2385-2390.
8. Sirianni MC, Vincenzi L, Topino S, *et al.*: Human herpesvirus 8 DNA sequences in CD8 + T cells. *J Infect Dis* 1997;176:541.
9. Sirianni MC, Uccini S, Angeloni A, Faggioni A, Cottoni F, and Ensoli B: Circulating spindle cells: Correlation with human herpesvirus-8 (HHV-8) infection and Kaposi's sarcoma. *Lancet* 1997;349:255.
10. Minami R and Yamamoto M: A case of HIV-1 and HHV-8-associated Castleman disease with a relapsing high fever and lymphadenopathy. *Kansenshogaku Zasshi* 2006;80:423-427.
11. Polstra AM, Van Den Burg R, Goudsmit J, and Cornelissen M: Human herpesvirus 8 load in matched serum and plasma samples of patients with AIDS-associated Kaposi's sarcoma. *J Clin Microbiol* 2003;41:5488-5491.
12. Kimura H, Morita M, Yabuta Y, *et al.*: Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. *J Clin Microbiol* 1999;37:132-136.
13. Nagai H, Wada K, Morishita T, Utsumi M, Nishiyama Y, and Kaneda T: New estimation method for highly sensitive quantitation of human immunodeficiency virus type 1 DNA and its application. *J Virol Methods* 2005;124:157-166.
14. Boivin G, Gaudreau A, Toma E, *et al.*: Human herpesvirus 8 DNA load in leukocytes of human immunodeficiency virus-infected subjects: Correlation with the presence of Kaposi's sarcoma and response to anticytomegalovirus therapy. *Antimicrob Agents Chemother* 1999;43:377-380.
15. Laney AS, Cannon MJ, Jaffe HW, *et al.*: Human herpesvirus 8 presence and viral load are associated with the progression of AIDS-associated Kaposi's sarcoma. *AIDS* 2007;21:1541-1545.
16. Aoki Y, Jones KD, and Tosato G: Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. *J Hematother Stem Cell Res* 2000;9:137-145.
17. Harrington W Jr, Sieczkowski L, Sosa C, *et al.*: Activation of HHV-8 by HIV-1 tat. *Lancet* 1997;349:774-775.
18. Lennette ET, Busch MP, Hecht FM, and Levy JA: Potential herpesvirus interaction during HIV type 1 primary infection. *AIDS Res Hum Retroviruses* 2005;21:869-875.
19. Wasmuth JC, Nischalke HD, Jütte A, *et al.*: Chemokine mRNA levels in mononucleated cells of HIV-infected patients before and after initiation of PI- versus NNRTI-containing HAART. *Antiviral Res* 2004;61:207-212.
20. Tamburini J, Grimaldi D, Chiche JD, Bricaire F, and Bossi P: Cytokine pattern in Kaposi's sarcoma associated with immune restoration disease in HIV and tuberculosis co-infected patients. *AIDS* 2007;21:1980-1983.
21. Tsai WH, Lee YM, Ing-Tiau Kuo B, *et al.*: Increased seroprevalence of human herpesvirus 8 in patients with hematological disorders. *Acta Haematol* 2005;114:95-98.
22. Cuzzola M, Irrera G, Iacopino O, *et al.*: Bone marrow failure associated with herpesvirus 8 infection in a patient undergoing autologous peripheral blood stem cell transplantation. *Clin Infect Dis* 2003;37:102-106.
23. Li Z, Nardi MA, and Karpatkin S: Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia. *Blood* 2005;106:572-576.
24. Sun Q, Matta H, Lu G, and Chaudhary PM: Induction of IL-8 expression by human herpesvirus 8 encoded vFLIP K13 via NF-kappaB activation. *Oncogene* 2006;25:2717-2726.
25. Kowalska MA, Ratajczak J, Hoxie J, Brass LF, Gewirtz A, Poncz M, and Ratajczak MZ: Megakaryocyte precursors, megakaryocytes and platelets express the HIV co-receptor CXCR4 on their surface: Determination of response to stromal-derived factor-1 by megakaryocytes and platelets. *Br J Haematol* 1999;104:220-229.
26. Henry M, Uthman A, Geusau A, *et al.*: Infection of circulating CD34 + cells by HHV-8 in patients with Kaposi's sarcoma. *J Invest Dermatol* 1999;113:613-616.
27. Wu W, Vieira J, Fiore N, *et al.*: KSHV/HHV-8 infection of human hematopoietic progenitor (CD34+) cells: Persistence of infection during hematopoiesis *in vitro* and *in vivo*. *Blood* 2006;108:141-151.
28. Quinn JP, Gilligan OM, and Horgan M: Evan's syndrome complicating multicentric Castleman's disease—dramatic response to rituximab. *Eur J Haematol* 2004;73:384-385.
29. Brown EE, Whitby D, Vitale F, *et al.*: Correlates of human herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma. *Int J Epidemiol* 2005;34:1110-1117.
30. Muela Molinero A, Ballesteros del Rio B, Sandoval Guerra V, and Llor Banos J: Evans syndrome as presentation of multicentric Castleman disease. *Rev Clin Esp* 2003;203:616-617.
31. Toyohama T, Nagasaki A, Miyagi J, *et al.*: Kaposi's sarcoma in a human immunodeficiency virus-negative patient treated with corticosteroid for idiopathic thrombocytopenic purpura. *Intern Med* 2003;42:448-449.

Address reprint requests to:

Rumi Minami  
Internal Medicine, Clinical Research Institute  
National Hospital Organization  
Kyushu Medical Center  
1-8-1 Jigyohama, Chuo-ku  
Fukuoka 810-8563, Japan

E-mail: rrrhh@kyumed.jp



## □ ORIGINAL ARTICLE □

## High Molecular Weight Form of Adiponectin in Antiretroviral Drug-induced Dyslipidemia in HIV-Infected Japanese Individuals Based on *in vivo* and *in vitro* Analyses

Rumi Minami, Masahiro Yamamoto, Soichiro Takahama, Hitoshi Ando, Tomoya Miyamura and Eiichi Suematsu

### Abstract

**Objective** High molecular weight (HMW)-adiponectin has been found to be a better negative regulator of insulin resistance than total adiponectin. The aim of this study was to investigate the influence of HMW-adiponectin on antiretroviral therapy (ART)-induced dyslipidemia in Japanese human immunodeficiency virus (HIV)-infected individuals. We also examined the effect of some antiretroviral drugs (ARVs) on adipocytes *in vitro*.

**Patients and Methods** Fifty-seven HIV-infected patients were enrolled in four clinical groups; (I) patients who started ART containing efavirenz (EFV); (II) patients who started ART containing a protease inhibitor without atazanavir (ATV); (III) patients who started ART containing ATV; (IV) patients who switched from ART without ATV into ART containing ATV. We measured the serum HMW-adiponectin before and one year after starting or changing ART, using an enzyme-linked immunosorbent assay (ELISA). Furthermore, we treated the mouse adipocytes (3T3-L1) with some ARVs. The lipid content was assessed using Oil Red O staining. The expression of adiponectin was measured by quantitative real-time PCR.

**Results** The serum HMW-adiponectin decreased significantly in groups (I) and (II) after starting ART, and increased significantly in group (IV) after changing from ART without ATV to ART with ART. EFV, ritonavir (RTV) and nelfinavir (NFV) inhibited the expression of adiponectin mRNA in mature 3T3-L1 and to a greater extent in pre-mature 3T3-L1. This phenomenon was reversible when ARV was changed to ATV.

**Conclusion** Effects of the ARVs on adiponectin may vary depending on the administration of different drugs. These data suggest that the distinct metabolic effects of ARV could therefore be a consequence of their differential effects on the production of adiponectin.

**Key words:** HMW-adiponectin, antiretroviral therapy, dyslipidemia

(Inter Med 48: 1799-1875, 2009)

(DOI: 10.2169/internalmedicine.48.2340)

### Introduction

Adiponectin is an adipokine secreted exclusively by adipocytes: this protein plays an important role in the control of systematic lipid metabolism and insulin sensitivity (1). Adiponectin forms multimers and is present in the serum as a trimer, hexamer, or as a high molecular weight (HMW) form (2). The HMW isoform most avidly binds to its recep-

tors and stimulates AMP-activated protein kinase, one of the key molecules mediating the metabolic actions of adiponectin.

Antiretroviral therapy (ART) has prolonged survival in human immunodeficiency virus (HIV)-infected individuals, but most individuals receiving ART develop metabolic abnormalities, which include dyslipidemia (elevated plasma triglycerides and cholesterol), increased visceral and dorsocervical adipose tissue and peripheral lipoatrophy (3). Although

HIV infection itself (4) and nucleoside reverse transcriptase inhibitors (NRTI) (5-7) have been associated with metabolic abnormalities, there are increasing clinical and epidemiological data that suggest a central role for HIV protease inhibitors (PIs) in the causation of metabolic complications (8) and atazanavir (ATV) use has been associated with a decrease in hyperlipidemia, less insulin resistance and reversal of lipodystrophy (9).

Several recent clinical studies suggest that hypoadiponectinemia might play an important role in the causation of metabolic abnormalities associated with HIV infected individuals treated with PI-based ART, especially for those with lipodystrophy (8, 10, 11), but to date, limited data have been published whether this hypoadiponectinemia is due to a disturbance of adipocyte differentiation, or to the decrease in the number of adipose cells number, or a dysfunction of adipocytes. In addition, there are still no data regarding the influence of antiretroviral drugs (ARVs) on serum HMW-adiponectin levels in Japanese, about 40% of whom have a genetic variation in the adiponectin gene associated with a reduced adiponectin level (12).

This study compared the effect on HMW-adiponectin level between ATV, PIs (except for ATV), ATV replacement therapy and non-nucleoside reverse transcriptase inhibitors (NNRTI), efavirenz (EFV) in HIV-infected Japanese subjects. In addition, the influence of each of the ARVs on adipocyte development and the expression of adiponectin were evaluated, using *in vitro* models.

## Materials and Methods

### Study population

The subjects evaluated in this study consisted of 57 HIV-positive patients admitted to National Hospital Organization Kyushu Medical Center, who started ART or were changing the ART combination. The present study was conducted in accordance with the regulations of the institutional ethics committee. These individuals were enrolled into four clinical groups; (I) patients who started ART containing EFV; (II) patients who started ART containing PIs without ATV; (III) patients who started ART containing ATV; (IV) patients who replaced the ART without ATV into ART containing ATV. The Body Mass Index (BMI), serum triglyceride, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, HMW adiponectin were measured before and one year after starting or changing ART. HMW-adiponectin was measured by enzyme-linked immunosorbent Assay (ELISA), using the Human Adiponectin ELISA kit for Total and Multimers (Daichi Pure Chemicals Co., Tokyo, Japan). Lipodystrophy was determined by a standardized, lipodystrophy-specific physical examination which recorded lipoatrophy and/or diffuse fat accumulation in the face, neck, dorsocervical spine, arms, breasts, abdomen, buttocks and legs.

### Cells

The 3T3-L1 cells were purchased from the Japanese Collection of Research Bioresources. The cells were maintained in DMEM supplemented with 10% fetal bovine serum. For differentiation, post confluent cells were induced by incubation with 0.5 mM 3-isobutyl-methylxanthine and 1  $\mu$ M dexamethasone for 2 days. This is followed by incubation with 10  $\mu$ g/mL insulin for 2 days. The cells were then maintained in Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum (FBS) for another 2 days. To investigate the effects of ARVs on adipogenesis, and to investigate the difference between the effect of ARVs on preadipocytes and the effect on mature adipocytes, several ARVs were added to the medium before and after differentiation of 3T3-L1 cells.

### Antiretroviral drugs

Efavirenz (EFV), ritonavir (RTV), nelfinavir (NFV) were purchased from Toronto Research Chemicals Inc. (Ontario, Canada). ATV was provided by Bristol-Myers Squibb Company (NY, USA). Drug stocks in dimethyl sulfoxide (DMSO) were stored at -20°C and diluted into culture media. Vehicle control incubations received the same final DMSO concentration as all drug-treated incubations (0.1%). The IC<sub>50</sub>/IC<sub>95</sub> and the C<sub>max</sub> of each drug are as follows; EFV (IC<sub>95</sub>=1.7-25nM, C<sub>max</sub>= 14.2-28.8  $\mu$ M), RTV (IC<sub>50</sub>=65-289nM, C<sub>max</sub>= 0.84-21.9  $\mu$ M), NFV (IC<sub>50</sub>=30-60nM, C<sub>max</sub>= 5.0-8.6  $\mu$ M), and ATV (IC<sub>50</sub>=2-5nM, C<sub>max</sub>=4.96-8.38  $\mu$ M). The cells were treated with 20  $\mu$ M of EFV, RTV and ATV and 10  $\mu$ M of NFV.

### Quantitative real time RT-PCR

Total cellular RNA was isolated from 3T3-L1 cells, using QIAamp RNA Blood Mini (QIAGEN, Tokyo, Japan), including treatment with DNase. cDNA was generated from the RNA using TAKARA RNA PCR kit (TAKARA BIO, Shiga, Japan). Real time PCR was conducted with the LineGene33 (BioFlux, Tokyo, Japan) using SYBR Green Realtime PCR Master Mix (TOYOBO Co, Osaka, Japan). As an internal control measurement, to normalize for input DNA, copy numbers of  $\beta$ -actin were determined in every sample tested. The ratio of the normalized mean value for drug-treated samples was calculated and is given in the graphs.

### Measurement of adiponectin levels in culture medium

The secretion of adiponectin from 3T3-L1 cells were determined by measuring the adiponectin concentration of culture medium, using the Mouse Adiponectin/Acrp30 Immunoassay (R&D systems, Mimmepolis, USA).

### Oil Red O staining

The cellular lipid content was assessed by lipid staining with Oil Red O. Staining was quantified at 520 nm after

Inter Med 48: 1799-1875, 2009 DOI: 10.2169/internalmedicine.48.2340

Table 1. Characteristics of 57 HIV-infected Individuals and the Changes of Metabolic Markers

|   | group I                  | group II                 | group III   | group IV (pre)           | group IV (post) |
|---|--------------------------|--------------------------|-------------|--------------------------|-----------------|
| Number of cases (M/F)   | 15 (13/2)                | 14 (13/1)                | 14 (13/1)   | 14 (12/2)                |                 |
| Mean age (SD) (years)   | 37.7 (10.8)              | 42.1 (14.2)              | 38.3 (9.1)  | 46.1 (12.6)              |                 |
| NRTI combination (number)(frequency %)                            |                          |                          |             |                          |                 |
| Abacavir/ lamivudine  | 0 (0)                    | 0 (0)                    | 1 (7.1)     | 0 (0)                    | 2 (14.3)        |
| Zidovudine/ lamivudine  | 4 (26.7)                 | 0 (0)                    | 4 (28.6)    | 5 (35.7)                 | 4 (28.6)        |
| Stavudine/ lamivudine   | 7 (46.7)                 | 7 (50)                   | 5 (35.7)    | 6 (42.9)                 | 4 (28.6)        |
| Didanosine/ lamivudine  | 0 (0)                    | 0 (0)                    | 0 (0)       | 2 (14.3)                 | 2 (14.3)        |
| Didanosine/ zidovudine  | 0 (0)                    | 2 (14.3)                 | 0 (0)       | 0 (0)                    | 0 (0)           |
| Tenofovir/ emtricitabine  | 4 (26.7)                 | 5 (35.7)                 | 4 (28.6)    | 1 (7.1)                  | 2 (14.3)        |
| the ratio of after to before starting or changing ART (mean (SE)) |                          |                          |             |                          |                 |
| Body Mass Index   | 1.00 (0.01)              | 0.99 (0.01)              | 1.02 (0.01) | 0.98 (0.04)              |                 |
| Tryglyceride  | 1.63 (0.19) <sup>*</sup> | 1.72 (0.24) <sup>*</sup> | 1.22 (0.17) | 1.00 (0.304)             |                 |
| HDL-cholesterol   | 1.29 (0.12) <sup>*</sup> | 1.17 (0.16)              | 1.14 (0.11) | 1.01 (0.07)              |                 |
| LDL-cholesterol   | 1.17 (0.12)              | 1.27 (0.12) <sup>*</sup> | 1.10 (0.05) | 0.85 (0.06) <sup>*</sup> |                 |
| HMW-adiponectin   | 0.61 (0.24) <sup>*</sup> | 0.65 (0.09) <sup>*</sup> | 1.19 (0.20) | 1.61 (0.11) <sup>*</sup> |                 |

P values are evaluated by one sample sign test. \* indicates significant difference (\* p<0.001, \*\* p<0.05)

NRTI, nucleoside reverse transcriptase inhibitor; ART, antiretroviral therapy

\*pre' indicates before changing ART, and \*post'indicates after changing ART.

solubilization, using an Adipogenesis Assay Kit (Chemicon International Temecula, CA, USA)

### Statistical analysis

To evaluate the changes of BMI, serum triglyceride, LDL-cholesterol, HDL-cholesterol, HMW-adiponectin after starting or changing ART, the one sample sign test was applied. The Mann-Whitney test was used to compare the serum HMW-adiponectin according to lipodystrophy. In vitro experiments were reproduced in at least three independent experiments. The results are presented as the mean  $\pm$  SD. Significance was determined as described in the figure legends.

## Results

### The effect of ARV on the lipid profile and HMW adiponectin

The demographic and clinical characteristics for the 57 patients included in the study are shown in Table 1. There were no significant differences in the age and the NRTI combinations used as the backbone of PIs or EFV among the four groups ( $\chi$ -square test). The serum triglycerides and LDL-cholesterol increased significantly in individuals in groups I and II and LDL-cholesterol decreased significantly in individuals with group IV. The serum HMW-adiponectin decreased significantly in individuals in groups I and II and increased significantly in individuals with group IV. On the other hand, there was no change in the triglyceride, LDL-cholesterol, and HMW-adiponectin levels in individuals in group III (Table 1). These results show that serum HMW-adiponectin level decreased in individuals with ART including EFV or PIs except ATV, but the decrease was reversible and it was recovered by changing the ART into that including ATV.

### HMW-adiponectin and lipodystrophy

The development of lipodystrophy was observed in 14 of the 43 patients who newly initiated ART (the patients of groups I, II, and III). Lipodystrophy was more prevalent in

group I (53.3%) and group II (28.6%) than in group III (14.3%). The differences in lipodystrophy were not driven by the overall weight gain. There was no significant difference in the serum HMW-adiponectin before ART between individuals with and without lipodystrophy followed by ART, but the serum HMW-adiponectin after starting ART and the ratio of HMW-adiponectin after to before starting ART decreased significantly in individuals with lipodystrophy (Fig. 1).

### The effect of ARV on adiponectin mRNA levels in differentiating 3T3-L1 cells

As shown in Table 1, the effect of ART on dyslipidemia and lipodystrophy differed among the ART menus, but it is nearly impossible to fully separate the effects of the drug classes in the clinical data, because the patients received a combination of several classes of ART. As a result, *in vitro* models were used to examine the precise influence of these drugs on adipocyte development or metabolism, using well-characterized preadipocyte 3T3-L1 cells. The concentrations of ARVs used in this assay were within the range (RTV, EFV) or a little higher (ATV, NFV) than what is generally observed in plasma from individuals receiving therapeutic doses of ARV. Considering that some ARVs can accumulate in fat tissue, it is possible that the effects of ARVs on 3T3-L1 cell lines observed *in vitro* may also occur *in vivo*. When pre-adipocytes were treated with ARV, lipid accumulation was severely reduced by EFV and NFV (Fig. 2A). The adiponectin mRNA level was reduced by RTV, EFV, NFV, and was not affected by ATV (Fig. 2B). Similar results were obtained concerning the secretion of adiponectin into the culture medium (Fig. 2C). Since it is possible that the effect of ARV on the adipocyte metabolism is known to differ between preadipocytes and mature adipocytes, the mature adipocytes were also treated with ARVs. Mature adipocytes were less sensitive to ARVs' effects on lipid accumulation and adiponectin mRNA level than premature adipocytes. Lipid accumulation was reduced by EFV, RTV and NFV (Fig. 2A). The adiponectin mRNA level was reduced by RTV, EFV, and NFV, whereas ATV did not affect the adi-

Inter Med 48: 1799-1875, 2009 DOI: 10.2169/internalmedicine.48.2340




Figure 1. The levels of serum HMW-adiponectin in HIV-infected individuals with/without lipodystrophy. (A) HMW-adiponectin before starting ART, (B) HMW-adiponectin after starting ART, (C) the ratio of HMW-adiponectin after starting ART to that before starting ART. The medians are indicated with horizontal bars. The vertical bars indicate the range between 10% and 90% and the horizontal boundaries of the boxes represent the interquartile range. P values are evaluated by the Mann-Whitney U-test. \*  $p < 0.01$ , \*\* $p < 0.05$  versus individuals without lipodystrophy. LD: lipodystrophy

ponectin mRNA level (Fig. 2B). Similar results were obtained concerning the secretion of adiponectin into the culture medium (Fig. 2C).

#### The effect of changing PI/EFV to ATV on adiponectin mRNA levels in 3T3-L1 cells

In the clinical study, the decreased adiponectin induced by PI/EFV was restored by switching the drugs to ATV. In addition, the precise effect of ATV on decreased adiponectin mRNA induced by PI/EFV was examined in vitro, using 3T3L1 cells. Adiponectin mRNA recovered significantly in mature adipocytes after switching drugs from EFV and NFV to ATV, but it did not recover on EFV- and NFV-treated pre-adipocytes and RTV-treated pre- and mature adipocytes (Fig. 3).

## Discussion

Several studies have reported that metabolic syndrome is more common in subjects with HIV infection than in HIV-negative individuals. Although uncontrolled HIV replication can cause an adverse modification of the lipid metabolism, these modifications can be mainly induced by ART. The present study described the lipid abnormalities and lipodystrophy associated with ART. Hypertriglyceridemia was more common than abnormalities of HDL cholesterol and LDL cholesterol. LDL cholesterol increases were only observed in the population of group II (PI without ATV). These abnormalities were recovered by changing ART to the ATV containing regimen. In HIV-negative populations, the most common features associated with metabolic syndrome are obesity and hypertension. On the other hand, in HIV-positive populations, hypertriglyceridemia and hypertension are reported to be common components and the most frequent abnormalities that lead to metabolic syndrome (3).

That is why HIV-positive patients might need to have their ART regimen tailored to their lipid abnormalities.

In this study, we also investigated the effect of ARVs on serum HMW-adiponectin, which has been reported to be a useful marker for evaluating insulin resistance and metabolic syndrome. This is the first study to investigate the influence of ARVs on the serum HMW-adiponectin levels in Japanese HIV-infected individuals. In general, the serum adiponectin levels are known to be inversely related to the adipose tissue mass (13). The serum adiponectin levels have been reported to rise when obese persons lose weight (14). We showed that adiponectin levels are relatively low in HIV-infected individuals with lipodystrophy who have a low fat mass, and this is consistent with previous reports (7, 10). These results suggest that the normal relationships between adiponectin concentration and adipose droplets appear to be lost or reversed in HIV-infected individuals. Since adiponectin expression is higher in subcutaneous fat than in visceral fat in humans (15), visceral fat accumulation and subcutaneous fat loss may thus lead to decreased adiponectin production both in lipoatrophic and lipohypertrophic patients. Therefore, fat redistribution may actually be responsible for the decreased adiponectin levels in HIV patients with lipodystrophy. As shown in Fig. 1(C), it is certain that some of the patients without lipodystrophy had a decrease in serum HMW-adiponectin levels, but these patients had dyslipidemia more frequently than the patients with either normal or high serum HMW-adiponectin without lipodystrophy (data not shown). Considering the fact that clinical HIV lipodystrophy has been reported to be associated with dyslipidemia, these patients might thus have the potential to be complicated by lipodystrophy. Therefore, the low levels of serum HMW-adiponectin are correlated with lipodystrophy and/or dyslipidemia induced by PIs and NNRTI (EFV).

The present study also showed the direct effects of ARVs